OncoCyte Corporation (OCX) Tops Q2 EPS by 27c

OncoCyte Corporation (NASDAQ: OCX) reported Q2 EPS of ($1.03), $0.27 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $362.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Qualcomm investor day to detail data center plans Wednesday
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance